Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

Related Keywords

Madrid ,Spain ,Mark Lanasa ,Luis Paz ,European Union ,Head Of The Medical Oncology Service ,European Medicines Agency ,European Commission ,Medicinal Products ,Human Use ,Solid Tumors ,Thoracic Oncology ,Medical Oncology Service ,Hospital Universitario ,Tislelizumab ,European Approval ,Non Small Cell Lung Cancer ,Nsclc ,